Upstream Bio, Inc. (UPB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has a cash flow conversion efficiency ratio of -0.059x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.24 Million) by net assets ($378.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UPB net asset quality score to measure how much of total assets are equity-financed.
Upstream Bio, Inc. - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Upstream Bio, Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
Upstream Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Upstream Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mia Teknoloji AS
IS:MIATK
|
0.025x |
|
AB Traction
ST:TRAC-B
|
0.030x |
|
CMC Magnetics Corp
TW:2323
|
0.000x |
|
Weltrend Semiconductor Inc
TW:2436
|
0.038x |
|
Waskita Karya Persero Tbk
JK:WSKT
|
0.035x |
|
Bangkok Land Public Company Limited
BK:BLAND
|
0.003x |
|
Everspin Technologies Inc
NASDAQ:MRAM
|
0.008x |
|
F-SECURE OYJ
HE:FSECURE
|
0.148x |
Annual Cash Flow Conversion Efficiency for Upstream Bio, Inc. (2022–2024)
The table below shows the annual cash flow conversion efficiency of Upstream Bio, Inc. from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Upstream Bio, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $469.85 Million | $-59.17 Million | -0.126x | -140.89% |
| 2023-12-31 | $-123.13 Million | $-37.93 Million | 0.308x | +71.91% |
| 2022-12-31 | $-106.16 Million | $-19.02 Million | 0.179x | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more